Trial Profile

A phase 1 study of IBI-101 in patients with advanced solid tumors in USA

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Dec 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cudarolimab (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

20 Dec 2018 New trial record
04 Dec 2018 According to an Innovent Biologics media release, the US FDA has excepted the company's IND application to initiate this phase 1 study. The company plans to initiate this study based on the results from the China phase I study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com